Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
A $1.5 billion US‑China biotech deal creates Sentivera, linking Haisco’s drug pipeline with American venture capital.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 6.
Source diversity sample: insights.citeline.com · Pharmaceutical Technology · Investing.com Nigeria · Investing.com · TradingView · Endpoints News · BioSpace · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Haisco, the Chinese drugmaker, secures a lucrative licensing stream for its pre‑clinical inflammatory‑disease candidate. The sequence began with Haisco licensing the pre‑clinical drug to the US venture, as detailed by Investing.com.
TradingView reported an exclusive license agreement with the newly formed venture founded by Population Health Partners and ARCH Venture Partners. BioSpace noted that the partnership brings up to $1.5 billion from American VCs to establish Sentivera, while Fierce Biotech highlighted the Metsera‑backed founders.
Today Sentivera is positioned as an immunology biotech with funding secured and an exclusive right to develop the Haisco candidate, a development framed by Endpoints News as part of a China‑centric investment blitz. No further terms or timelines have been disclosed.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (86% supported) Updated 5h ago.
The reporting (8)
- Haisco Inks Second Deal This Year With A Startup, Worth Up To $1.5bn-Plus insights.citeline.com · 23h ago
- Metsera backers establish new biotech armed with China-licensed immunology asset Pharmaceutical Technology · 23h ago
- Haisco licenses pre-clinical drug to US venture for $1.5 billion Investing.com Nigeria · 23h ago
- Haisco licenses pre-clinical drug to US venture for $1.5 billion Investing.com · 23h ago
- Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners TradingView · 23h ago
- ARCH and Population Health join China blitz with Haisco deal Endpoints News · 23h ago
- China’s Haisco forms immunology biotech with up to $1.5B from American VCs BioSpace · 23h ago
- Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal Fierce Biotech · 23h ago
Quick answers
Who are the primary investors behind Sentivera?
The primary investors are ARCH Venture Partners and Population Health Partners, with backing from Metsera backers.
What is the financial scope of the agreement between Haisco and the US venture?
The agreement involves up to $1.5 billion in licensing and funding.
Which therapeutic area does the partnership focus on?
The collaboration targets inflammatory disease treatments within immunology.
Topics
Related trends
Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback
Massachusetts' biotech industry faces a paradox: job losses and a rebound in investment.
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s multi‑billion deal for Hanmi’s muscle‑sparing obesity drug sparks anticipation for a new weight‑loss option
NUS researchers find drug that turns off ‘master switch’ in aggressive breast cancer
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough from Moderna and Merck has investors and patients hopeful, but challenges remain
A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.
A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High
Amylyx Pharmaceuticals' stock surges after a GLP-1 antagonist drug shows promise in a new application.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.